Gen-Probe v. Abbott
This article was originally published in The Gray Sheet
Gen-Probe's HIV and hepatitis C nucleic acid test for donated blood screening does not infringe Abbott subsidiary Vysis' patent 5,750,338, a jury decides May 22. Abbott says it is reviewing its position but Gen-Probe expects an appeal. In addition to finding the '338 patent invalid, the U.S. Southern District Court of California jury also determines that "Vysis engaged in inequitable conduct in the course of obtaining the patent and...should be charged with unreasonable delay in the patent prosecution," according to Gen-Probe...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.